Septerna director Alan Ezekowitz sells $3.93M in SEPN stock

Septerna director Alan Ezekowitz sold 81,820 shares of the company's common stock on November 11, 2026, for a total of $3.93 million. The shares were sold at a price range of $46.005 to $51.9 per share. Since the sale, the stock has fallen to $42.60, a 13% decrease over the past week, despite an 83% gain over the previous year. These transactions were carried out under a Rule 10b5-1 sales plan Ezekowitz established on July 13, 2026.

Currently, Ezekowitz owns 35,600 shares directly. According to InvestingPro, the stock is considered undervalued and highly volatile, with a beta of 2.2. For further insights, investors can explore more than 10 ProTips and detailed financial metrics on the platform. Septerna Inc has recently received feedback from various financial firms about its drug pipeline and stock value.

Guggenheim raised its price target to $65, upgrading its rating to Buy, citing a 50% improved chance of success for their oral small molecule PTH replacement, SEP-479. They also adjusted risk-adjusted sales estimates for SEP-204, a Graves' disease treatment, to a 10% success probability. Wells Fargo similarly raised its price target to $61, keeping an Overweight rating, and anticipates a favorable Phase 1 readout in Q1 2027 if SEP-479 is successful. These updates illustrate shifts in the company's financial and drug development strategies.